News
Presence of Risk Factors Associated with Colectomy in Patients with Ulcerative Colitis in Studies with Tofacitinib
One of the important goals of active ulcerative colitis therapy is the prevention of colectomy. A clinical study, the results of which were recently presented at the Vienna UEG (United European Gastroenterology) congress, evaluated the association of risk factors and the use of tofacitinib with colectomy in patients with active ulcerative colitis in the OCTAVE clinical trial program.
Prof. Petr Marusič: Is the Success of Therapy Changing with the Arrival of New Antiepileptics?
At the XXV. postgraduate course in epileptology, 'Jiří Dolanský Days', prof. MUDr. Petr Marusič,…
Severe Polytrauma in a Man with von Willebrand Disease − Case Report
The authors of a recently published case report present a case of multiple trauma (including brain…
Substitution Treatment of von Willebrand Disease with vWF and FVIII Concentrates
Recently published recommendations from Poland regarding the diagnosis and treatment of von…
ITP from the Patients' Perspective: How It Affects Their Lives and Which Needs They Find Unmet?
In recent years, new therapeutic options for immune thrombocytopenia (ITP) have been introduced,…
Can we finally reliably distinguish between viral and bacterial pneumonia, or identify the specific cause? Promising results from a nanoparticle-based test
The etiology of pneumonia involves a wide range of pathogens, and distinguishing between bacterial…
Benefits of Physical Activity for Individuals with Hemophilia – Recommendations of the MEMO Group
Regular physical activity can increase joint stability and function in individuals with hemophilia,…
Romiplostim Before Splenectomy in a Patient with ITP - Case Report
In the following case report from authors at a university hospital in Barcelona, the successful use…
Effectiveness of Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Clinical Practice
One of the new modalities for the treatment of ulcerative colitis (UC) is tofacitinib. Its…
Fresh data from real clinical practice on targeted treatment of RA with etanercept: Should therapy be changed after 12 weeks due to insufficient response?
A recently published German study investigated, among other things, what percentage of patients…